BackgroundCheck.run
Search For

Srdjan R Stankovic, 67Boston, MA

Srdjan Stankovic Phones & Addresses

Boston, MA   

New London, CT   

New Hope, PA   

15 Alexander Dr, Flemington, NJ 08822    404-2714573   

26 Talmadge Ln, Basking Ridge, NJ 07920   

Marietta, GA   

Hoover, AL   

Mendham, NJ   

Mentions for Srdjan R Stankovic

Srdjan Stankovic resumes & CV records

Resumes

Srdjan Stankovic Photo 28

President

Location:
Boston, MA
Industry:
Pharmaceuticals
Work:
Neurogene
Member Board of Directors
Acadia Pharmaceuticals Inc.
President
Acadia Pharmaceuticals Inc. Nov 2015 - Nov 2018
Executive Vice President, Head of Research and Development at Acadia Pharmaceuticals Inc
Alkermes Jul 2013 - Nov 2015
Senior Vice President, Clinical Development and Medical Affairs
Teva Pharmaceuticals Jun 2010 - Jan 2013
Senior Vice President, Head of Global Clinical Development
Forest Laboratories Jun 2009 - Jun 2010
Senior Vice President, Fri
Neurogen Corporation Apr 2008 - May 2009
Executive Vice President and Chief Development Officer
Cephalon Mar 2005 - Mar 2008
Vice President
Johnson & Johnson Feb 2003 - Mar 2005
Senior Director and Compound Development Leader
Ucb Aug 1997 - Feb 2003
Vice President
Education:
University of Alabama at Birmingham 1990 - 1991
Masters, Master of Science In Public Health, Epidemiology
University of Belgrade 1983 - 1987
University of Belgrade 1974 - 1980
Doctor of Medicine, Doctorates, Medicine
Srdjan Stankovic Photo 29

Srdjan Stankovic

Publications & IP owners

Us Patents

Pimavanserin Alone Or In Combination For Use In The Treatment Of Alzheimer's Disease Psychosis

US Patent:
2020023, Jul 30, 2020
Filed:
Dec 14, 2017
Appl. No.:
16/471543
Inventors:
- San Diego CA, US
James Randall Owen - Princeton NJ, US
Mark Donald Knowles - San Diego CA, US
Srdjan R. Stankovic - Flemington NJ, US
James M. Youakim - Bryn Mawr PA, US
International Classification:
A61K 31/4468
A61K 9/00
A61P 25/28
A61P 25/18
A61K 31/13
A61K 31/27
A61K 31/473
A61K 31/445
A61K 31/549
A61K 31/55
Abstract:
Methods for the treatment of Alzheimer's disease psychosis, or a symptom thereof, comprising administering pimavanserin. Also provided herein are methods for the treatment of delusions and/or hallucinations in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing NPI-NH score in a human with Alzheimer's Disease comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing agitated behavior or aggressive behavior in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.